최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기大韓韓方婦人科學會誌 = The Journal of Korean obstetrics & gynecology, v.32 no.4, 2019년, pp.144 - 158
정소미 (경희대학교 대학원 임상한의학과) , 황덕상 (경희대학교 한의과대학 부인과교실) , 이진무 (경희대학교 한의과대학 부인과교실) , 이창훈 (경희대학교 한의과대학 부인과교실) , 장준복 (경희대학교 한의과대학 부인과교실)
Objectives: The purpose of this study is to report the effect of Korean medical treatment in case of germ cell tumor patient treated by chemotherapy. Methods: The patient was treated with Korean medical treatment (herbal medicine, acupuncture) for 11 months. By taking computed tomography and laborat...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
난소암은 암이 발생하는 조직에 따라 어떻게 구분되는가? | 난소암은 암이 발생하는 조직에 따라 상피성 종양(Epithelial Cancer), 생식세포 종양(Germ Cell Tumor), 그리고 성삭기질 종양(Sex Cord-Stromal Tumor)으로 구분된다. 이 중 난소의 상피세포에서 발생하는 상피성 종양이 전체 난소암의 90% 이상에 해당하며, 비상피성 종양 중 악성 난소 생식세포 종양은 전체난소암의 0. | |
난소 생식세포종양(Germ Cell Tumor)은 무엇인가? | 난소 생식세포종양(Germ Cell Tumor)은 난소의 난자를 만드는 세포 즉, 원시생식세포에서 유래하는 종양이다. 악성난소생식세포 종양은 조직형에 따라 미분화 세포종(Dysgerminoma), 내배엽동종양(Endodermal Sinus Tumor), 미성숙기형종(Immature Teratoma), 융모암(Choriocarcinoma) 다배아종(Polyembryoma), 혼합 생식세포종(Mixed germ cell tumor)로 분류된다. | |
항암화학요법은 암 세포뿐만 아니라 정상 세포에도 영향을 주기 때문에 다양한 부작용이 생기는데, 어떠한 것들이 있는가? | 하지만 항암화학요법은 암 세포뿐만 아니라 정상 세포에도 영향을 주기 때문에 다양한 부작용이 발생하게 된다. Bleomycin, Etoposide, Cisplatin 병합 항암화학요법의 부작용은 골수 억제로 인한 백혈구 감소증, 위장관계 독성으로 인한 오심과 구토, 식욕저하, 탈모 및 피부 반응, 말초 신경병증, 폐 독성(Bleomycin), 신 독성(Cisplatin) 등이 있다4). 이러한 부작용은 환자의 삶의 질을 심각하게 떨어뜨려 환자로 하여금 항암치료의 지속을 주저하게 만든다. |
The Society of Korean Medicine Obstetrics and Gynecology. Oriental Obstetrics & Gynecology. Seoul:Publishing Co. Eui Seong Dang. 2012:347-52.
Ministry of Health and Welfare, National Cancer Control Institute. Cancer registration.Statistics Program. 2016.
Jacobs IJ, et al. Screening for ovarian cancer: a pilot randomized controlled trial. Lancet. 1999 Apr 10;353(9160):1207-10.
Nogales FF, et al. Germ cell tumors of the ovary: an update. Arch Pathol Lab Med. 2014;138(3):351-62.
Nawa A, et al. Prognostic factors of patients with yolk sac tumors of the ovary. Am J Obstet Gynecol. 2001;184(6):1182-8.
Williams SD, et al. Adjuvant therapy of ovarian germ cell tumors with cisplaitn, etoposide, and bleomycin : a trial of the Gynecologic Oncology Group. Gynecol Oncol. 2004;95(3):496-9.
David M, et al. Managemnt of Early Ovarian Cancer: Germ cell and Sex Cord-Stromal Tumors. Gynecol Oncol. 1994;55(3):562-72.
Zanetta G, et al. Survival and reproductive function after treatment of malignant germ cell ovarian tumors. J Clin Oncol. 2001;19(4):1015-20.
Lee KW, et al. A Preliminary Study for Development of Clinical Practice Guidelines of Korean Medicine in Breast Cancer. The Journal of Korean Obstetrics and Gynecology. 2016;29(2):47-66.
Mead GM, et al. The International Germ Cell Consensus Classification : a new prognostic factor-based staging classification for metastatic germ cell tumors. Clin Oncol. 1997;9(4):207-9.
Kim CM, et al. The encyclopedia of oriental herbal medicine. Publishing Co. Jungdam. 1997;(7):3473-9.
Wang JH, et al. 20(s)-ginsenoside Rg3 promotes apoptosis in human ovarian cancer HO-8910 cells through PI3K/Akt and XIAP pathways. Tumour Biol. 2014;35(12):11985-94.
Xu TM, et al. Inhibitory effect of ginsenoside Rg3 on ovarian cancer metastasis. Chin Med J (Engl). 2008;121(15):1394-7.
Ting Liu, et al. Ginsenoside 20(S)-Rg3 Targets HIF- $1{\alpha}$ to Block Hypoxia-Induced Epithelial-Mesenchymal Transition in Ovarian Cancer Cells. PLoS ONE. 2014;9(9):e103887.
Li J, et al. Ginsenoside 20(S)-Rg3 inhibits the Warburg effect through STAT3 pathways in ovarian cancer cells. Int J Oncol. 2015;46(2):775-81.
Zheng X, et al. Ginsenoside 20(S)-Rg3 induced autophagy to inhibit migration and invasion of ovarian cancer. Biomed Pharmacother. 2017;85:620-6.
National Compilation Committee of Korean Medicine college(全國韓醫科大學共同敎材編纂委員會). Herbalogy (本草學) Seoul:Publishing Co. Young rim. 2016:320-4.
Kang H, et al. Astragali Radix Increases Survival and Activity of Spleen Lymphocyte. Journal of physiology & pathology in Korean medicine. 2001;15(4):560-5.
Cho WC, et al. In vitro and in vivo anti-tumor effects of Astragalus membranaceus. Cancer Lett. 2007;252(1):43-54.
Evan GI, et al. Proliferation, cell cycle and apoptosis in cancer. Nature. 2011;411(6835):342-8.
Park JG, et al. Effects of Astragalus membranaceus Extract on Cell Cycle and Apoptosis of Human Leiomyoma Cell. The Journal of Korean Obstetrics and Gynecology. 2008;21(2):49-58.
Lee DH, et al. A case report of metastatic breast cancer treated with korean medicine therapy as a substitute for chemotherapy. Case Rep Oncol. 2017;10(1):27-36.
Shin MG. Clinical Traditional Herbalogy. Seoul:Publishing Co. Young-rim. 1989:55-7
Song MS, et al. The Study of Literature Review on Lacas Sinicia Exsiccate. The Journal of Korean Obstetrics and Gynecology. 2002;15(1):61-76.
David D.Kitts, et al. Antitumorigenic and cytotoxic properties of an ethanol extract dervied from Rhus Verniciflua Stokes. J Toxical Environ Health A. 2001;64(4):357-71.
Oh PS, et al. Glycoprotein Isolated from Rhus verniciflua stokes Inhibits Inflammation-Related Protein and Nitric Oxide Production in LPS-Stimulated RAW 264.7 Cells. Biol Pharm Bull. 2007;30(1):111-6.
Nancy A. The caspase family of cysteine proteases. British Medical Bulletin. 1997;53(3):478-90.
Lee JH. The effect of G2 cell cycle arrest in ATM/ATR-cdc25c-cdc2-cyclin B pathway by Butein-the active material of Rhus verniciflua stokes in Human breast cancer MCF-7 cell lines. Department of Oriental Medicine, Kyung Hee Graduate School. 2010.
Jang HJ. Molecular mechanism by which Resina Toxicodendrii induces apoptosis and suppresses chemo-resistance in MCF-7/DOX cells. Department of Clinical Korean Medicine, Kyung Hee Graduate School. 2017.
Williams P, et al. Apoptosis: Pharmacological Implications and Therapeutic Opportunities. Mayo Clinic Proceedings. 1998;73(9):917.
Kwon SJ, et al. EuiMunChuiEeon (醫門贅言) Wonju:Publishing Co. Eui bang 2014:124-6.
Lee JD. The Physio-pathology of Oriental Medicine with 30 Essential Herbal Formulas. Seoul:Publishing Co. Jeong-dam. 2015:414-40.
Kwon SW, et al. Korean Internal Medicine Diagnosis&Treatment (韓方內科診察診斷治療) Goyang:Guide. Gaonhamedia. 2017:84-8.
Dundee JW, et al. Acupuncture prophylaxis of cancer chemotherapy-induced sickness. J R Soc Med. 1989;82(5):268-71.
Ohno T, et al. Rikkunshito, a traditional Japanese medicine, suppresses cisplatin -induced anorexia in humans. Clin Exp Gastroenterol. 2011;4(1):291-6.
Lin JC, et al. Phase III Study of Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Advanced Nasopharyngeal Carcinoma: Positive Effect on Overall and Progression-Free Survival. J Clin Oncol. 2003;21(4):631-7.
Huddart RA, et al. A randomised phase 2 trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP in poor-prognosis germ cell tumours (MRC TE23, CRUK 05/014, ISRCTN 53643604). Eur Urol. 2015;67(3):534-43.
Tryakin A, et al. Paclitaxel+BEP (T-BEP) regimen as induction chemotherapy in poor prognosis patients with non-seminomatous germ cell tumors: a phase II study. Urology. 2011;78(3):620-5.
Kier MG, et al. Prognostic Factors and Treatment Results After Bleomycin, Etoposide, and Cisplatin in Germ Cell Cancer: A Population-based Study. Eur Urol. 2017;71(2):290-8.
Chang HJ, et al. A case of Ovarian Mixed Germ cell tumor with rapid relapse. Journal of Gynecologic Oncology. 2002;13(2):171.
Kim CS, et al. A Literature Review of the East-West Medical Combined Treatment) Korean Institute of Oriental Medicine. 2012;18(2):101-16.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
출판사/학술단체 등이 한시적으로 특별한 프로모션 또는 일정기간 경과 후 접근을 허용하여, 출판사/학술단체 등의 사이트에서 이용 가능한 논문
※ AI-Helper는 부적절한 답변을 할 수 있습니다.